Aldosterone-receptor antagonism and end-stage renal disease

Current Hypertension Reports

Volumn 6, Issue 4, 2004, Pages 327-330

  McLaughlin, Niall ^a   Gehr, Todd W B ^a   Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DEOXYCORTICOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; KIDNEY RENIN; MINERALOCORTICOID; NORADRENALIN; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ANURIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GYNECOMASTIA; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE; PATIENT MONITORING; PERITONEAL DIALYSIS; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 4344642203     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0029-1     Document Type: Article

References (47)

1. Brunner HR, Laragh JH, Baer L, et al.: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972, 286:441-449.
2. Alderman MH, Madhavan S, Ooi WL, et al.: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991, 324:1098-1104.
3. SOLVD Investigators 1992: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1992, 327:685-691.
4. Pfeffer MA, Braunwald E, Moyé LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992, 327:669-677.
5. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
6. Jafar TH, Schmid CH, Landa M, et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
7. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
8. Lewis EJ, Hunsicker LC, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
9. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
10. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
11. Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
12. Hunt SA, Baker DW, Chin MH, et al.: ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2001, 104:2996-3007.
13. Grundy SM, Howard B, Smith S Jr, et al.: Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002, 105:2231-2239.
14. Dzau VJ: Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001, 37:1047-1052.
15. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
16. Sun Y, Ramires FJ, Weber KT: Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997, 35:138-147.
17. Delcayre C, Silvestre JS, Garnier A, et al.: Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000, 57:1346-1351.
18. Takeda Y, Yoneda T, Demura M, et al.: Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens 2001, 19:635-639.
19. Takeda Y, Miyamori I, Yoneda T, et al.: Production of aldosterone in isolated rat blood vessels. Hypertension 1995, 25:170-173.
20. Rocha R, Martin-Berger CL, Yang P, et al.: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143:4828-4836.
21. Yalcin AU, Dincer M, Aslan V, Gulbas Z: Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 2002, 25:260-264.
22. Brown NJ, Vaughan DE, Fogo AB: Aldosterone and PAI-1: implications for renal injury. J Nephrol 2002, 15:230-235.
23. Feria I, Pichardo I, Juarez P, et al.: Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003, 63:43-52.
24. Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689-1697.
25. Fardella CE, Mosso L, Gómez-Sánchez C, et al.: Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000, 85:1863-1867.
26. Epstein M: Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med 2001, 94:378-383.
27. Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
28. Struthers A: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995, 16(SuppN):103-106.
29. Allon M: Treatment and prevention of hyperkalemia in end-stage renal disease. Kidney Int 1993, 43:1197-1209.
30. Salem MM, Rosa RM, Battle DC: Extra renal potassium tolerance in chronic renal failure: implications for the treatment of hyperkalemia. Am J Kid Dis 1991, 18:421-440.
31. Papadimitriou M, Vyzantiadis A, Milionis A, et al.: The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation. Life Support Syst 1983, 1:197-205.
32. Vlassopoulos D, Sonikian M, Dardioti V, et al.: Insulin and mineralocorticoid influence on extrarenal potassium metabolism in chronic hemodialysis patients. Ren Fail 2001, 23:833-842.
33. Sugarman A, Brown RS: The role of aldosterone in potassium tolerance: studies in anephric humans. Kidney Int 1988, 34:397-403.
34. Sato A, Funder JW, Sanna T: Involvement of aldosterone in left ventricular hypertrophy of patients with end stage renal failure treated with haemodialysis. Am J Hypertens 1999, 12:867-873.
35. Nitta K, Akiba T, Nihei H: Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med 2003, 115:250.
36. Foster ES, Jones WJ, Hayslett JP, et al.: Role of aldosterone and dietary potassium in potassium adaptation in the distal colon of the rat. Gastroenterology 1985, 88:41-46.
37. Bastl CP, Hayslett JP: The cellular action of aldosterone in target epithelia [editorial]. Kidney Int 1992, 42:250-264.
38. Sandle GI, Gaiger E, Tapster S, Goodship TH: Evidence for large intestinal control of potassium homeostasis in uremic patients undergoing long-term dialysis. Clin Sci 1987, 73:247-252.
39. Matsuda K, Shimamoto K, Ura N, et al.: A case of primary aldosteronism with chronic renal failure undergoing hemodialysis treatment. Endocrinol Jpn 1989, 36:681-686.
40. Charron RC, Leme CE, Wilson DR, et al.: The effect of adrenal steroids on stool composition as revealed by in vivo dialysis of feces. Clin Sci 1969, 37:151-167.
41. Overdiek HW, Merkus FW: The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact 1987, 5:273-302.
42. Gardiner P, Schrode K, Quinlan D, et al.: Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 1989, 29:342-347.
43. Ravis WR, Reid S, Roniker B, et al.: Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. Clin Pharmacol Ther 2004, 75:P37.
44. Hausmann MJ, Liel-Cohen N: Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. Nephrol Dial Transplant 2002, 17:2035-2036.
45. Hussain S, Dreyfus DE, Marcus RJ, et al.: Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 2003, 18:2364-2368.
46. Saudan P, Mach F, Perneger T, et al.: Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 2003, 18:2359-2363.
47. Schohn DC, Jahn HA, Pelletier BC: Dose-related cardiovascular effects of spironolactone. Am J Cardiol 1993, 71:40A-50A.